News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
667 Results
Type
Article (35)
Company Profile (1)
Press Release (631)
Section
Business (221)
Career Advice (1)
Deals (23)
Drug Development (172)
FDA (10)
Job Trends (5)
News (437)
Policy (43)
Tag
Alliances (21)
ALS (4)
Approvals (6)
Artificial intelligence (1)
Best Places to Work (1)
Cancer (11)
Cardiovascular disease (1)
Career advice (1)
Cell therapy (1)
Clinical research (159)
Collaboration (2)
Complete response letters (4)
COVID-19 (1)
Data (4)
Depression (1)
Diabetes (1)
Drug discovery (1)
Earnings (144)
Events (57)
Executive appointments (1)
FDA (15)
Funding (2)
GLP-1 (1)
Government (2)
Healthcare (31)
Immunology and inflammation (1)
Infectious disease (1)
IPO (18)
Job creations (2)
Job search strategy (1)
Legal (10)
Machine learning (1)
Manufacturing (1)
Medical device (1)
Medtech (1)
Mergers & acquisitions (5)
Metabolic disorders (2)
Multiple sclerosis (1)
Neuropsychiatric disorders (1)
Neuroscience (6)
Now hiring (2)
Obesity (1)
Ovarian cancer (11)
People (68)
Pharmaceutical (1)
Phase 1 (16)
Phase 2 (74)
Phase 3 (77)
Pipeline (1)
Postmarket research (6)
Preclinical (10)
Rare diseases (1)
Regulatory (42)
Series B (1)
Startups (1)
Vaccines (3)
Date
Last 7 days (1)
Last 30 days (3)
Last 365 days (42)
2026 (7)
2025 (35)
2024 (31)
2023 (27)
2022 (28)
2021 (29)
2020 (35)
2019 (15)
2018 (11)
2017 (40)
2016 (32)
2015 (44)
2014 (37)
2013 (53)
2012 (50)
2011 (47)
2010 (40)
Location
Asia (12)
Australia (3)
California (36)
China (1)
Europe (33)
Georgia (1)
Indiana (1)
Massachusetts (2)
Nevada (1)
Northern California (31)
Pennsylvania (1)
South America (1)
Southern California (3)
United States (41)
667 Results for "corcept therapeutics.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.
January 26, 2026
·
2 min read
·
Tristan Manalac
Complete response letters
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings
Corcept’s relacorilant was rejected for hypercortisolism late last year—a decision which CEO Joseph Belanoff expressed surprise with at the time.
February 2, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
January 23, 2026
·
7 min read
Complete response letters
FDA Rejects Corcept and Outlook Filings, Crushing Stock Prices
Both companies received agency requests for more evidence of the effectiveness of their therapies.
January 2, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
January 1, 2026
·
3 min read
ALS
Corcept Claims Survival Benefit in ALS Despite Missed Endpoint
Analysts at Truist Securities called the mid-stage data a “mixed bag,” also flagging gastrointestinal adverse events. However, the readout is unlikely to be “incremental” to Corcept’s overall stock narrative.
June 6, 2025
·
2 min read
·
Tristan Manalac
Press Releases
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
September 11, 2025
·
4 min read
Press Releases
Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics
October 2, 2025
·
2 min read
Press Releases
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 28, 2025
·
1 min read
Press Releases
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
November 4, 2025
·
14 min read
1 of 67
Next
